Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care
This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany.
Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.
Inclusion Criteria:
Exclusion Criteria:
medinfo.germany@abbvie.com49 611 1720 1520
Freiburg im Breisgau, Baden-Wurttemberg 79098, Germany
Munich, Bavaria 81541, Germany
Planegg, Bavaria 82152, Germany
Hohen Neuendorf, Brandenburg 16540, Germany
Bad Endenbach, Hesse 35080, Germany
Frankfurt am Main, Hesse 60329, Germany
Braunschweig, Lower Saxony 38106, Germany
Kassel, Lower Saxony 34125, Germany
Neubrandenburg, Mecklenburg-Vorpommern 17033, Germany
Schwerin, Mecklenburg-Vorpommern 19053, Germany
Meerbusch, North Rhine-Westphalia 40668, Germany
Monheim am Rhein, North Rhine-Westphalia 40789, Germany
Kaiserslautern, Rhineland-Palatinate 67657, Germany
Wittlich, Rhineland-Palatinate 54516, Germany
Zweibrücken, Rhineland-Palatinate 66482, Germany
Dresden, Saxony 01097, Germany
Leipzig, Saxony 04109, Germany
Magdeburg, Saxony-Anhalt 39104, Germany
Naumburg, Saxony-Anhalt 06618, Germany
Rendsburg, Schleswig-Holstein 24768, Germany
Pfarrkirchen, 84347, Germany